PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC)

10.1200/jco.2004.22.14_suppl.831 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 831-831 ◽

Cited By ~ 4

Author(s):

M. De Wit ◽

N. Harbeck ◽

C. Thomssen ◽

K. Becker ◽

A. Psonka ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase

Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)

Investigational New Drugs ◽

10.1007/s10637-008-9166-8 ◽

2008 ◽

Vol 27 (2) ◽

pp. 166-172 ◽

Cited By ~ 11

Author(s):

G. Schilling ◽

M. Bruweleit ◽

N. Harbeck ◽

C. Thomssen ◽

K. Becker ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Combination Chemotherapy ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase

A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).

10.1200/jco.2016.34.15_suppl.tps625 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS625-TPS625 ◽

Cited By ~ 1

Author(s):

Antonio Llombart-Cussac ◽

Meritxell Bellet ◽

Pilar Zamora ◽

Manuel Ruiz ◽

Joseph Gligorov ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Open Label ◽

A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.

10.1200/jco.2011.29.15_suppl.508 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 508-508 ◽

Cited By ~ 14

Author(s):

F. Andre ◽

T. D. Bachelot ◽

M. Campone ◽

F. Dalenc ◽

J. M. Perez-Garcia ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Open Label ◽

Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer.

10.1200/jco.2010.28.15_suppl.tps122 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS122-TPS122 ◽

Cited By ~ 4

Author(s):

F. Andre ◽

J. Baselga ◽

M. J. Ellis ◽

S. A. Hurvitz ◽

H. S. Rugo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Open Label ◽

Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

10.1158/1538-7445.sabcs20-ps10-17 ◽

2021 ◽

Author(s):

José Manuel Pérez-García ◽

Antonio Llombart-Cussac ◽

Meritxell Bellet ◽

Florence Dalenc ◽

Miguel J. Gil Gil ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Safety Analysis ◽

Open Label ◽

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Annals of Oncology ◽

10.1093/annonc/mdz100.001 ◽

2019 ◽

Vol 30 ◽

pp. iii47 ◽

Cited By ~ 2

Author(s):

J. Huober ◽

K. Ribi ◽

P. Weder ◽

Q. Li ◽

L. Vanlemmens ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC)

10.1200/jco.2004.22.90140.831 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 831-831

Author(s):

M. De Wit ◽

N. Harbeck ◽

C. Thomssen ◽

K. Becker ◽

A. Psonka ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase

Abstract PS10-57: A randomized, multicenter, open-label phase II/III study of ARX788 vs Lapatinib and Capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer (ZMC-ARX788-211)

10.1158/1538-7445.sabcs20-ps10-57 ◽

2021 ◽

Author(s):

Xichun Hu ◽

Jian Zhang ◽

Leiping Wang ◽

Gang Xia ◽

Yanping Ji ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Locally Advanced ◽

Metastatic Breast ◽

Her2 Positive ◽

Open Label ◽

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71443-5 ◽

2011 ◽

Vol 47 ◽

pp. S330 ◽

Cited By ~ 25

Author(s):

S. Hurvitz ◽

L. Dirix ◽

J. Kocsis ◽

L. Gianni ◽

J. Lu ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽